13D Filings
CASI Pharmaceuticals, Inc.
CASI
Amendment
Ownership

34.80%

Total Shares

8,965,535

Issuer CIK

1962738

CUSIP

G1933S101

Event Date

Jan 26, 2026

Accepted

Jan 29, 2026, 07:21 PM

Reporting Persons (7)
NameType% of ClassAggregateSole VotingShared Voting
WEI-WU HE, Ph.D.
Individual
34.80%8,965,5352,130,5506,834,985
ETP Global Fund III L.P.
Partnership
19.60%5,000,00005,000,000
EMERGING TECHNOLOGY PARTNERS, LLC
Other
5.30%1,097,34101,097,341
ETP Global Fund L.P.
Partnership
3.70%753,2340753,234
HUIYING MEMORIAL FOUNDATION
CO
3.10%637,6440637,644
ETP BIOHEALTH III FUND, L.P.
Partnership
1.50%300,0000300,000
HE Family GRAT
Other
0.50%100,0000100,000
Disclosure Items (7)

Security Title

Ordinary Shares

Issuer Name

CASI Pharmaceuticals, Inc.

Issuer Address

1701-1702, CHINA CENTRAL OFFICE TOWER 1, BEIJING, F4, 100025

Item 2(a)-(f) of the Schedule 13D is hereby amended and supplemented by the following: ETP Global Fund III L.P. is a limited partnership organized under the laws of Delaware and controlled by Dr. Wei-Wu He. The business address of ETP Global Fund III L.P. is 4919 Rebel Ridge Dr, Sugar Land, TX 77878.

As described in Item 4 below, on December 27, 2025, ETP Global Fund III L.P. purchased a convertible note with a principal amount of US$5 million using its working capital pursuant to certain Note Purchase Agreement between ETP Global Fund III L.P. and the Issuer dated December 11, 2025.

On December 27, 2025, ETP Global Fund III L.P. purchased a convertible note with the principal amount of US$5 million as the first tranche of the Issuer's US$20 million convertible note financing pursuant to certain convertible note purchase agreement (the "Purchase Agreement") between ETP Global III Fund L.P. and the Issuer dated December 11, 2025. A convertible note with a principal amount of US$5 million has been issued to the Purchaser on the same date (the "Convertible Note"). The Purchaser has the right to convert such note into the Company's ordinary shares, par value US$0.0001 per share (the "Ordinary Shares") at any time from and including the 91st day after the issuance thereof to and including the maturity date at a conversion price of the volume weighted average closing price of the Company's Ordinary Shares during the five consecutive trading days immediately preceding the date of conversion notice by ETP Global Fund III L.P. In no event shall the conversion price be higher than US $2 per Ordinary Share or lower than US $1 per Ordinary Share. The descriptions of the Convertible Note are qualified in their entirety by reference to the Convertible Note itself, a copy of which is attached hereto as Exhibit B and incorporated hereby by reference in its entirety. The beneficial ownership reported hereof included Ordinary Shares that the reporting person has the right to acquire within 60 days, through the conversion of such Convertible Note, with an assumed conversion price of US $1, given consideration of the average volume-weighted closing price of the Company's Ordinary Shares of US$0.98 for the last five trading days.

Percentage of Class

See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person. The percentage used in this Schedule 13D is calculated based upon 20,555,873 Ordinary Shares outstanding as of January 28, 2026.

Number of Shares

See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

Transactions

See Item 4, Purpose of Transaction.

Shareholders

No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

Date of 5% Ownership

Not applicable.

The descriptions of the principal terms of the Proposal under Item 4 are incorporated herein by reference in their entirety. To the best knowledge of the Reporting Persons, except as provided herein and disclosed before, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Persons and between any of the Reporting Persons and any other person with respect to any securities of the Company, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies, or a pledge or contingency, the occurrence of which would give another person voting power over the securities of the Company.

Exhibit A Joint Filing Agreement by and among ETP Global Fund LP, Emerging Technology Partners LLC, ETP BioHealth III Fund, LP, HE Family GRAT and Wei-Wu He, Ph.D. dated April 18, 2023. Exhibit B Convertible Note, dated December 27, 2025, issued to ETP Global Fund III L.P.

CASI Pharmaceuticals, Inc. — Schedule 13D | 13D Filings